SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC

SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC is a phase 2, randomised interventional study registered as NCT07198165 by Ruijin Hospital, with a registry enrolment figure of 104 participants, started 2025-09-05 and due to reach its primary completion in 2030-12-31. Interventions recorded: PD-1 inhibitor based immunotherapy. Conditions listed: Rectal Cancer; Rectal Adenocarcinoma; Rectal Cancer, Radiotherapy; Rectal Cancer Patients; Immunotherapy; Total Neoadjuvant Therapy; Total Neoadjuvant Treatment; Targeted Therapy; Chemoradiotherapy. Primary outcome: Complete Response rate. Colorectal eligibility wording from the registry: "* Histopathologically confirmed rectal adenocarcinoma with no prior antitumor therapy". Sites: China. No results are recorded here; the registry entry is the source.